Altimmune SEC Filings

Wayne Pisano, a director of Altimmune, Inc. (ALT), was granted stock options to purchase 48,800 shares of common stock at an exercise price of $3.92 per share. The options are exercisable beginning on 09/25/2025 and expire on 09/25/2035. The grant vests in substantially equal monthly installments over the 12 months following 09/25/2025, subject to continued service. Following the reported transaction, the reporting person beneficially owns 48,800 option shares, held directly.

Altimmune insider grant summary: Linda M. Richardson, listed as Chief Commercial Officer and a director, reported equity awards on 09/16/2025. She was awarded stock options to purchase 278,000 shares with an exercise price of $3.63 and restricted stock units representing 96,000 shares. Both awards vest over four years, with 25% vesting on September 16, 2026, and the remainder vesting in installments thereafter; the options expire September 16, 2035. Following the transaction, Richardson beneficially owns 278,000 option shares and 96,000 RSUs as reported. The filing was signed by an attorney-in-fact on 09/17/2025.

Altimmune, Inc. (ALT) Form 3: Linda M. Richardson submitted an initial Section 16 Form 3 reporting relationship to Altimmune as Chief Commercial Officer and a director-level officer. The filing states the date of the event as 09/16/2025 and the Form was signed by an attorney-in-fact on 09/17/2025. The Form explicitly notes no securities are beneficially owned by the reporting person and includes Exhibit 24 (Power of Attorney).

Altimmune, Inc. (ALT) is holding a virtual 2025 Annual Meeting of Stockholders on September 25, 2025 at 8:30 a.m. Eastern accessible at https://www.cstproxy.com/altimmune/2025 using a 12-digit control number. The proxy statement presents routine governance items: election of directors, ratification of Ernst & Young (E&Y) as independent auditors for the year ending December 31, 2025, an annual advisory "say-on-pay" vote on named executive officer compensation, and authorization to adjourn the meeting.

The filing references corporate governance materials and the Company Code of Ethics available on the investor relations site and notes the Audit Committee received PCAOB-required disclosures from E&Y and recommended inclusion of audited financial statements in the 2024 Form 10-K. Named executive officers listed for 2024 include Vipin K. Garg, Ph.D. (CEO), M. Scott Harris, M.D. (CMO), and M. Scot Roberts, Ph.D. (CSO). Benefit highlights include a 401(k) Plan with a 100% match on the first 4% of participant contributions. The statement also describes director nomination processes and related-party/merger background.

Altimmune reported strong clinical topline results from its IMPACT Phase 2b MASH trial, where weekly pemvidutide produced MASH resolution rates of 59.1% (1.2 mg) and 52.1% (1.8 mg) versus 19.1% for placebo (p<0.0001 for both doses). Fibrosis improvement by conventional ITT analysis was not statistically different, but an AI-based analysis showed a larger fibrosis reduction signal (30.6% of subjects on 1.8 mg achieved ≥60% fibrosis reduction versus 8.2% on placebo, p<0.001). Pemvidutide also drove mean weight loss of 5.0% and 6.2% at 1.2 mg and 1.8 mg versus 1.0% for placebo, and safety/tolerability appeared favorable with low discontinuation rates.

On the balance sheet, cash and equivalents were $183.1M at June 30, 2025, the company drew $15.0M of a $100M term loan facility (effective interest rate 14.4%), and generated net proceeds of $72.6M from at-the-market equity offerings in the period plus an additional $12.8M raised in July. The company recorded a six-month net loss of $41.7M and has an accumulated deficit of $603.1M. A class action alleging securities law violations was filed on August 5, 2025.